science-translational-medicine
Science Translational Medicine (science-translational-medicine)
Journal positioning
Science Translational Medicine is an AAAS journal occupying the explicit mechanism-to-bedside tier of translational research: every paper must demonstrate both a mechanistic insight and a credible arc toward clinical application — a drug, device, biomarker, or intervention that shows measurable clinical plausibility in human subjects or validated preclinical-to-clinical bridging. This dual mandate distinguishes Sci Transl Med from JCI (which may publish mechanism with human corroboration but without an explicit clinical translation arm) and from Nature Medicine (which requires broader significance but not necessarily a translation demonstration). The readership is translational researchers, physician-scientists, biotech and pharma scientists, and clinical investigators who need both the mechanism and the "so what for the clinic" in the same paper.
This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the AAAS / Science Translational Medicine platform.
When to trigger
- The author names Sci Transl Med or AAAS translational as the target venue.
- A mechanism-plus-clinical-arm paper needs venue selection among Sci Transl Med, JCI, and Nature Medicine.
- A preclinical study with a human proof-of-concept pilot or biomarker validation component needs framing guidance.
- The author needs Sci Transl Med's desk-reject risks and a ranked alternative list before submitting.